Brimonidine/ dorzolamide/ timolol - Laboratorios Sophia

Drug Profile

Brimonidine/ dorzolamide/ timolol - Laboratorios Sophia

Alternative Names: Krytantek PF; PRO-122

Latest Information Update: 29 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Laboratorios Sophia
  • Class Antiglaucomas; Antihypertensives; Eye disorder therapies; Ischaemic heart disorder therapies; Morpholines; Propanolamines; Quinoxalines; Small molecules; Sulfonamides; Thiadiazoles; Thiophenes
  • Mechanism of Action Alpha 2 adrenergic receptor agonists; Beta-adrenergic receptor antagonists; Carbonic anhydrase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Ocular hypertension

Most Recent Events

  • 04 Aug 2017 Laboratorios Sophia S.A de C.V. initiates the phase III PRO-122LATAM trial in Ocular hypertension in Mexico (Ophthalmic) (NCT03193333)
  • 04 Aug 2017 Clinical trials in Ocular hypertension in Mexico (Ophthalmic)
  • 28 Jun 2017 Laboratorios Sophia plans a phase III non-inferiority trial for Ocular hypertension in patients with open-angle glaucoma (Opthalmic, preservative free solution) (NCT03193333)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top